Raplon is an
anesthetic manufactured by Organon, Inc. and approved by the Food and Drug Administration in August of 1999. Raplon is used to complement
general anesthesia in order to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.
On March 30, 2001 Organon announced that it was withdrawing Raplon from the market after several reports of severe adverse reactions in patients taking Raplon. Such side effects include, but may not be limited to,
bronchospasm and
death. Organon informed
doctors to remove all packages of Raplon from their shelves immediately.
If you have experienced adverse side effects after receiving Raplon, it may be important to speak with your healthcare professional. Additionally, you may wish to
contact an attorney who can help you protect your legal rights. Please keep in mind that there may be
time limits within which you must commence suit.
See Also
- Anesthetics: Overview
- Bronchospasm: Overview